



Supplemental Figure 1. c-KITmut is associated with resistance to PARPi olaparib, but not to doxorubicin in CBFB-MYH11 –positive AMLs. Clonogenic potential of Lin-CD34+ cells from individual AML patients harboring CBFB-MYH11 (CM), CBFB-MYH11 + c-KITmut (CMK) and CBFB-MYH11 + NRASmut (CMR) treated with the indicated concentrations of olaparib or doxorubicin. **(A)** Mean percentage of colonies from individual samples tested in triplicates. **(B)** Mean percentage \pm SD of colonies compared to untreated counterparts from the samples harboring the same mutations.

Table 1. Genetic aberrations in freshly diagnosed AML samples from E1900 clinical trial.

Translocation	Acc#	c-KITmut	NRASmut
	14751		
	18488		
	19079		
CBFB-MYH11	16327	D816V	
	18871	FS (418)	
	19512	FS(418)	
	15453		G13D
	18026		G12D
	18917		Q61K
	15835	FS (418)	
AML1-ETO	19135	D816V	
	19537	FS (418)	
	18310		
	19356		
	14969		
	17298		